Gamma-glutamyl transferase as a risk factor for mortality and cardiovascular events in older adults – results from a prospective cohort study in a primary care setting (getABI)
Abstract
Summary.Background: In primary care, the gamma-glutamyl transferase (GGT) activity is used for assessing hepatobiliary dysfunction, but is also known to be associated with the risk of cardiovascular events as well as overall mortality. As this knowledge is mainly based on cohorts with middle-aged participants, we aim to assess these associations in elderly patients in a primary care setting. Patients and methods: 6,880 unselected primary care patients, aged 65 years or older, were enrolled by 344 general practitioners all over Germany (getABI study). During seven years of follow-up, coronary heart disease (CHD) events (myocardial infarction or coronary revascularization), cerebrovascular events (stroke or carotid revascularization) and deaths were recorded. Event rates were calculated and Cox regression analysis with adjustment for age, gender, GGT, classical and other risk factors (e.g. education, homocysteine, C-reactive protein, vitamin D) was performed. Results: 1,243 patients died. 27.8 deaths per 1,000 patient years (0.95 confidence interval [0.95 CI]: 26.2–29.3) occurred in the whole cohort. 605 participants had a CHD event, i.e. 16.1 per 1,000 patient years (0.95 CI: 14.8–17.4). 296 cerebrovascular events were observed, i.e. 7.7 per 1,000 patient years (0.95 CI: 6.9–8.6). Cox regression analysis with adjustment for the above-mentioned risk factors showed a significant impact of baseline elevation of GGT above the 3rd quartile (women > 18 U/L, men > 26 U/L) compared to the rest on mortality (hazard ratio [HR] 1.38, 95% CI 1.22–1.56, p < 0.001) and cerebrovascular events (1.39, 95% CI: 1.08–1.79), p = 0.010), whereas the association with CHD events (HR: 1.16, 95% CI: 0.97–1.39, p = 0.103) showed no significance. Conclusions: In a primary care setting, GGT values have a significant association with overall mortality and cerebrovascular events, but not with CHD events in elderly patients.
References
1 . Gamma-glutamyltransferase as a cardiovascular risk factor. Eur Heart J. 2006;27:2145–6.
2 . Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease triggering oxidative stress within the plaque. Circulation. 2005;112:2078–80.
3 . Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4:481.
4 . Gamma-glutamyltransferase: determinants and association with mortality from ischaemic heart disease and all causes. Am J Epidemiol. 1995;142:699–708.
5 . Gammaglutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163 944 Austrian adults. Circulation. 2005;112:2130–7.
6 . Distribution, determinants, and prognostic value of gammaglutamyltranspeptidase for all-cause mortality in a cohort of construction workers from south Germany. Prev Med. 1997;26:305–10.
7 Serum γ-Glutamyltranspeptidase Predicts All-cause, Cardiovascular and Liver Mortality in Older Adults. J Clin Exp Hepatol. 2013;3:4–11.
8 Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int. 2014;34:296–304.
9 . Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int. 2009;29:1494–9.
10 The risk of peripheral artery disease in older adults – seven-year results of the getABI study. Vasa. 2016;28:1–8.
11 Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.
12 Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–33.
13 . Classifying Educational Programmes – Manual for ISCED-97 Implementation in OECD Countries 1999 Edition, (1999). http://www.oecd.org/edu/skills-beyond-school/1962350.pdf.
14 . Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
15 . Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem. 2007;53:940–6.
16 Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study. Sci Rep. 2018;8:3764.
17 . Serum gammaglutamyl transferase, self-reported alcohol drinking, and the risk of stroke. stroke. 2000;31:1851–5.
18 Gammaglutamyltransferase and risk of stroke: the EUROSTROKE project. J Epidemiol Community Health. 2002;56(Suppl 1):i25–9.
19 . The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis. 2008;201:168–75.
20 γ-Glutamyltranspeptidase and incident stroke among Japanese men and women. The Circulatory Risk in Communities Study (CIRCS). Stroke. 2009;41:385–8.
21 Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. PLoS One. 2018;13:e0194153. doi: 10.1371/journal.pone.0194153. eCollection 2018.
22 Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J. 2006;27:2170–6.
23 . Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 2014;236:7–17.
